1. Market Research
  2. > Healthcare
  3. > Medical Device Market Trends
  4. > Global Artificial Organs Industry

Global Artificial Organs Industry

  • August 2016
  • -
  • Global Industry Analysts
  • -
  • 248 pages

This report analyzes the worldwide markets for Artificial Organs in US$ Million by the following Product Segments: Artificial Heart, Artificial Kidneys, Artificial Liver, Artificial Pancreas, and Artificial Lungs. The report provides separate comprehensive analytics for the US, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 48 companies including many key and niche players such as -

Abbott Diabetes Care, Inc.
Abiomed, Inc.
Asahi Kasei Medical Co., Ltd.
Baxter International, Inc.
F.Hoffmann-La Roche Ltd.

Table Of Contents

Global Artificial Organs Industry


I. INTRODUCTION, METHODOLOGY and PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1 Disclaimers.............. I-2 Data Interpretation and Reporting Level I-2 Quantitative Techniques and Analytics I-3 Product Definitions and Scope of Study I-3 Artificial Organs..............I-3 Artificial Heart.............. I-3 Artificial Kidneys.............. I-4 Artificial Liver.............. I-4 Artificial Pancreas..............I-4 Artificial Lungs.............. I-4

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW.............. II-1 Artificial Organs Revolutionize Medical Technology Industry II-1 Growth Drivers.............. II-1 Growth Inhibitors.............. II-2 Artificial Organs Poised to Witness Significant Demand II-3 The United States - A Dominant Force in the Artificial Organs Market.............. II-3 Artificial Kidneys Garner a Larger Pie in the Artificial Organs Market.............. II-4 Competitive Scenario..............II-5 Technological Advancements Spearheading Growth II-5

2. ANALYSIS BY SEGMENT..............II-6 Artificial Heart.............. II-6 Table 1: Artificial Heart Transplants Worldwide (1969-2016): Percentage Share Breakdown of Number of Heart Transplants (includes corresponding Graph/Chart) II-6 Medical Community Poised to Embrace Artificial Heart II-7 Ventricular Assist Devices..............II-8 Select Ventricular Assist Devices II-9 Artificial Mechanical Heart Valves Come of Age II-9 Artificial Kidney.............. II-10 Kidney Failure: A Major Concern II-10 Artificial Kidney or Dialyzers Market II-10 Major Initiatives in the Artificial Kidney Space II-11 The Kidney Project..............II-11 Current Status of the Kidney Project II-12 Wearable Artificial Kidney Holds Promise to Transform Dialysis II-13 Artificial Liver.............. II-13 Liver Support System to Provide Precious Time for Liver Transplantation.............. II-13 Liver Assist Devices Competitive Landscape II-14 Select Liver Assist Devices..............II-14 Artificial Pancreas.............. II-14 Artificial Pancreas Device System Market Presents Lucrative Opportunities.............. II-14 Market Overview.............. II-15 Scientific Community Inches towards Artificial Pancreas System II-16 Competition and Key Developments in Artificial Pancreas Space II-17 Artificial Pancreas Status in the US II-18 Key Concerns.............. II-19

3. MARKET TRENDS AND ISSUES..............II-20 The Grim Reality of Mounting Economic and Social Burden of Cardiovascular Disease..............II-20 Table 2: Prevalence of Heart Failure in Select Countries (includes corresponding Graph/Chart) II-20 Artificial Pancreas System (APS) - The Future of Diabetes Care II-21 Higher Development Costs and Lengthy Regulatory Process - Stumbling Blocks for Product Commercialization II-21 Lack of Requisite Expertise - Hindering Implantation Process II-22 Xenotransplantation - Other Alternative to Donor Organ Shortage II-22 Artificial Organs from Cloned Animal Cells - A Promising Trend II-22 Immunosuppressants Hold Promise in Artificial Organs Market II-22 Move towards Smaller Implantable Devices II-22 Barriers to Entry Significantly High in Dialyzers Market II-23 Reuse of Dialyzers - A Major Issue in Dialysis Industry II-23 Poor Reimbursement Environment Stymies Innovation II-23 Product Recalls - A Major Blow to the Manufacturers II-23 Higher Cost of Artificial Organs Hampers Broader Adoption II-24 Major Issues Related to Artificial Organs II-25 Financial.............. II-25 Legal.............. II-26 Ethical.............. II-26 Social.............. II-26

4. MACRO FACTORS IMPACTING THE ARTIFICIAL ORGANS MARKET II-27 Aging Population: A Strong Growth Driver II-27 Global Aging Population Statistics - Opportunity Indicators II-27 Table 3: Elderly Population (60+ Years) as a Percentage of Total Population (2015 and 2050) (includes corresponding Graph/Chart).............. II-27

Table 4: Global Aging Population in Select Regions/Countries: Population of 60+ Individuals in ‘000s and as a Percentage of Total Population for 2015 and 2050 (includes corresponding Graph/Chart) II-28

Table 5: Life Expectancy at Age 60 and 80 Years - (2010-2015), (2020-2025) and (2045-2050) (includes corresponding Graph/Chart)..............II-29

Table 6: Life Expectancy for Select Countries in Number of Years: 2015E (includes corresponding Graph/Chart) II-30 Expanding Pool of ESRD and CKD Patients - The Major Growth Driver for Kidney Dialysis Treatment II-31 Table 7: Increasing Number of ESRD Patients Worldwide: 2014-2018 (includes corresponding Graph/Chart) II-31

Table 8: ESRD Prevalence in Select Countries (2014): Number of ESRD Patients Per Million Population in EU-28, Japan, Taiwan, USA and Global (includes corresponding Graph/Chart) II-32 Dialysis Market to Stage Steady Growth Amid Rising Prevalence of Kidney Diseases..............II-32 Table 9: Global Population of ESRD Patients Undergoing Treatment by Type of Modality (2010, 2015E and 2020P): Percentage Breakdown of Patients Undergoing Dialysis Therapy, and Kidney Transplantation (includes corresponding Graph/Chart).............. II-33 Developed Markets Maintain Lead, Emerging Markets to Dictate Momentum.............. II-34 Table 10: Worldwide Distribution of Dialysis Patients by Geographic Region (2015): Percentage Breakdown of Patient Population (includes corresponding Graph/Chart) II-35 Rising Incidence of Diabetes: Opportunity Indicator for Artificial Pancreas..............II-35 Growing Number of Type 1 Diabetes Cases II-35 Global Diabetic Statistics - Opportunity Indicators II-36 Table 11: Top 10 Countries for Number of Children with Type 1 Diabetes (2015) (includes corresponding Graph/Chart) II-36

Table 12: Global Prevalence of Type 1 Diabetes in Children by Region (2015) (includes corresponding Graph/Chart) II-37 A “Silent Killer” in Both Developed as well as Developing Nations.............. II-37 Table 13: Global Diabetes Mellitus Incidence among Ages 20-79 (2015 and 2040P): Prevalence (in Million) and Percentage Share by Geographic Region (includes corresponding Graph/Chart).............. II-38

Table 14: Top Ten Countries Worldwide with the Highest Number of People (in the Age Group 20-79 Years) with DM (in Millions): 2015 (includes corresponding Graph/Chart) II-39 Dialysis Patient Population: An Opportunity Indicator for Artificial KIdneys.............. II-39 Table 15: Global Dialysis Patient Population by Geographic Region/Country (2014-2018): Breakdown of Patient Population for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World (includes corresponding Graph/Chart) II-40 Distribution of Dialysis Patients by Modality II-40 Table 16: Worldwide Dialysis Patient Population by Treatment Modality (2015): Percentage Breakdown of Hemodialysis (HD) Patients and Peritoneal Dialysis (PD) Patients for US, Japan, European Union, and Rest of World (includes corresponding Graph/Chart).............. II-41

Table 17: Global Dialysis Patient Population Distribution by Modality for Select Countries (2015): Percentage Breakdown of Hemodialysis (HD) Patients and Peritoneal Dialysis (PD) Patients for US, China, Japan, Brazil, Mexico, Germany, India, Taiwan, Turkey, Thailand, Korea, Italy, France, Egypt, and Malaysia (includes corresponding Graph/Chart) II-42

5. 3D BIOPRINTING - A GAME CHANGER FOR THE ARTIFICIAL ORGANS INDUSTRY II-43 Application of 3D-Printing in the Medical Field II-44 3D Printing Revolutionizing the Medical Industry's Artificial Organ Development Segment..............II-45 Issues to be Tackled..............II-46 Sophisticated Software - A Key Element for 3D Printing II-47 Bioprinters to Aid Medical Students II-48 Bioprinters to Print Organs..............II-48 Bioprinters for Printing Defective Organs for Surgeons to Practice On.............. II-48

6. TECHNOLOGICAL ADVANCEMENTS..............II-50 New Artificial Pancreas with Sensor to Improve Insulin Management II-50 Researchers at the University of California Come Up with an Artificial Kidney..............II-50 Wearable Artificial Kidney Enters the US FDA's EAP Pipeline II-51 New Artificial Pancreas System to Improve Diabetes Management II-52 Production of 3D-like Artificial Organs in a Device that Works like a Cotton Candy Machine..............II-52 Harvard Scientists Create Tissue Containing Blood Vessels II-53 University of Washington Researchers Create Communicating Yeast Cells.............. II-53 ALung Technologies Develops Hemolung RAS Artificial Lung II-54 The First Transplant of Small Sized Artificial Heart for Petite People Carried Out in California II-55 Scientists Define Morphospace to Evaluate Viability of Artificial Organs..............II-55

7. PRODUCT OVERVIEW.............. II-57 Artificial Organs.............. II-57 Categorization of Artificial Organs II-57 External Artificial Organs..............II-57 Internal or Implantable Artificial Devices II-57 Artificial Heart.............. II-57 Total Artificial Heart (TAH)..............II-58 Ventricle Assist Device (VAD) II-58 Table 18: Distribution of Various Uses of VADs (includes corresponding Graph/Chart)..............II-58 Right Ventricular Assist Systems (RVAS) II-58 Left Ventricular Assist Systems (LVAS) II-58 Categorization of LVAS..............II-58 First Generation LVAS..............II-59 Second Generation LVAS..............II-59 Third Generation LVAS..............II-59 Benefits of LVAS.............. II-60 Major Limitations and Complications of VADs II-60 Infection.............. II-61 Internal Bleeding..............II-61 Thrombus.............. II-61 Dependability.............. II-61 Cost.............. II-62 Natural Human Heart..............II-62 Heart Diseases.............. II-62 Congenital Heart Disease..............II-62 Congestive Heart Failure..............II-62 Types of Heart Failure..............II-62 Diastolic Heart Failure..............II-63 Systolic Heart Failure..............II-63 Artificial Heart - A Historical Perspective II-63 Major Milestones in Artificial Heart Development II-64 Jarvik-7.............. II-64 AbioCor Total Artificial Heart II-64 CardioWest Temporary Total Artificial Heart II-65 DuraHeart LVAS.............. II-65 HeartSaverVAD.............. II-66 VentrAssist Left Ventricular Assist Device II-66 Artificial Kidney (Dialyzer)..............II-67 Limitations of Artificial Kidney II-67 Types of Dialysis..............II-67 Hemodialysis.............. II-67 Peritoneal Dialysis..............II-68 Advancements in Artificial Kidney Technology II-69 Bioartificial Kidneys..............II-69 Limitations of Bioartificial Kidneys II-69 Hindrances to Develop Implantable Artificial Kidney II-70 Artificial Kidneys - A Historical Perspective II-70 Artificial Liver.............. II-70 Overdose of Drugs - A Leading Cause for Liver Damage II-71 Categorization of Liver Devices II-72 Mechanical Systems..............II-72 Liver Dialysis Unitâ„¢..............II-72 Bio-Artificial Systems..............II-72 Capillary Hollow Fiber Systems II-73 Direct Perfusion Systems..............II-73 Entrapment Based Systems..............II-73 Major BAL Devices..............II-74 Extracorporeal Liver Assist Device (ELAD) II-74 Hybrid Artificial Liver Support System II-74 History of Artificial Liver..............II-75 Liver Assist Devices - Major Milestones II-75 Nonbiological Method Introduction Time Line II-75 Biological Method Introduction Time Line II-76 Artificial Pancreas.............. II-76 Insulin Pumps - Historical Perspective II-77 Bioartificial Pancreas..............II-77 Nanotechnology in Artificial Pancreas II-78 Artificial Lungs (Oxygenator)..............II-78 About Human Lungs..............II-78 Types of Artificial Lung..............II-79 Intravenous Membrane Oxygenator II-79 Hattler Respiratory Catheter..............II-79 MC3 Pulmonary Assist Device..............II-80 In-Series.............. II-80 In-Parallel.............. II-80 BioLung.............. II-80 Heart-Lung Bypass Machine..............II-80 Role of Artificial Lungs during Surgery II-80 Direct Contact Device..............II-81 Indirect-Contact Type-Membrane Devices II-81 Biorubber to be used in Artificial Lungs II-81 History of Artificial Lungs..............II-81 An Overview of Tissue Engineering II-81

8. INTRODUCTION TO BIOMATERIALS..............II-83

9. ORGAN TRANSPLANTATION..............II-84 Europe and the United States Lead the Global Organ Transplants Market.............. II-84 Table 19: Global Organ Transplants Market (2014 and 2015): Number of Actual Deceased Organ Donors Per Million Population (PMP) by Select Country (includes corresponding Graph/Chart) II-84

Table 20: Global Organ Transplants Market (2014 and 2015): Number of Living Organ Donors Per Million Population (PMP) by Select Country (includes corresponding Graph/Chart) II-85

Table 21: Global Organ Transplants Market (2014): Number of Actual Donors After Cardiac Death Per Million Population (PMP) by Select Country (includes corresponding Graph/Chart) II-85

Table 22: Global Heart Transplants Market (2014): Number of Transplants Per Million Population (PMP) by Select Country (includes corresponding Graph/Chart) II-86

Table 23: Global Kidney Transplants Market (2014): Number of Deceased Donors Per Million Population (PMP) by Select Country (includes corresponding Graph/Chart) II-86

Table 24: Global Kidney Transplants Market (2014): Number of Living Donors Per Million Population (PMP) by Select Country (includes corresponding Graph/Chart) II-87

Table 25: Global Liver Transplants Market (2014): Number of Deceased Donors Per Million Population (PMP) by Select Country (includes corresponding Graph/Chart) II-87

Table 26: Global Liver Transplants Market (2014): Number of Living Donors Per Million Population (PMP) by Select Country (includes corresponding Graph/Chart) II-88

Table 27: Global Pancreas Transplants Market (2014): Number of Transplants Per Million Population (PMP) by Select Country (includes corresponding Graph/Chart) II-88

Table 28: Global Lung Transplants Market (2014): Number of Transplants Per Million Population (PMP) by Select Country (includes corresponding Graph/Chart) II-89 Sources of Donor Organs..............II-89 Table 29: US Kidney Donations by Donor Type - Cadaveric and Living for Years 2010 through 2016 (includes corresponding Graph/Chart).............. II-90

Table 30: US Liver Donations by Donor Type - Cadaveric and Living for Years 2010 through 2016 (includes corresponding Graph/Chart).............. II-90

Table 31: US Heart Donations by Cadaveric Donor Type for Years 2010 through 2016 (includes corresponding Graph/Chart) II-91

Table 32: US Lung Donations by Donor Type - Cadaveric and Living for Years 2010 through 2016 (includes corresponding Graph/Chart).............. II-91

Table 33: US Pancreas Donations by Donor Type - Cadaveric and Living for Years 2010 through 2016 (includes corresponding Graph/Chart).............. II-92

Table 34: European Organ Transplants Market (2014 and 2015): Number of Actual Deceased Organ Donors Per Million Population (PMP) by Select Country (includes corresponding Graph/Chart) II-92

Table 35: European Organ Transplants Market (2014 and 2015): Number of Living Organ Donors Per Million Population (PMP) by Select Country (includes corresponding Graph/Chart) II-93 Shortage of Donor Organs Restricts Transplantation Procedures II-93 Table 36: Waiting List of Patient Registrations in the US by Organ Type: As of July 2016 (includes corresponding Graph/Chart).............. II-94 Organ Rejection - A Major Barrier to Transplantation II-94 Other Issues for Organ Transplantation II-94 Illegal Organ Trafficking - A Risky Proposition II-94 Ethical Concerns in Transplants..............II-95 Bioethical Issues Hinder Organ Donation Process II-95 Increasing Consent Rates - A Key Factor II-95 Combined Organ Transplantation - Gaining Attention II-95 Transplant Tourism - Creating Brighter Avenues II-96

10. REGULATORY ENVIRONMENT..............II-97 Regulatory Environment in the US II-97 Regulatory Environment in Europe II-98

11. PRODUCT INNOVATIONS/INTRODUCTIONS II-99 Medtronic Launches MiniMed(TM) 640G System II-99 Pandorum Develops Artificial Human Liver Tissue II-99

12. RECENT INDUSTRY ACTIVITY..............II-100 Medtronic and HeartWare International Ink Merger Agreement II-100 SynCardia Systems Inks an Agreement with Versa Capital Management II-100 Vivonics Sells Artificial Lung Technology to Lung Biotechnology PBC..............II-100 Insulet Corporation Enters into a Partnership and License Agreement with Mode AGC..............II-100 Cellnovo Group Enters into a Partnership with TypeZero II-100 St. Jude Medical Acquires Thoratec II-100 Debiotech Collaborates with ARTORG Center to Develop Artificial Pancreas..............II-101 DreaMed Diabetes Enters into an Agreement with Medtronic II-101 Breethe Acquires Exclusive Rights from University of Maryland II-101 SynCardia Systems Bags FDA Approval for SynCardia Temporary Total Artificial Heart's Destination Therapy Study II-101 HeartWare International Bags Approval from Health Canada for HeartWare® Ventricular Assist System II-101 Alung Technologies Announces Participation in the Pivotal Trial of ECCO2R Technology..............II-101 ALung Technologies Announces EAP Designation for Hemolung RAS II-101 Debiotech, AWAK and Neokidney Development Ink Join Venture Agreement.............. II-102 Carmat Implants Artificial Heart II-102 Baxter International Acquires Gambro II-102 Thoratec Acquires DuraHeart® II from Terumo II-102 Sunshine Heart Enters into Collaboration with Minnetronix(R) II-102 TandemDiabetes Care Enters into a Partnership with JDRF II-102

13. FOCUS ON SELECT GLOBAL PLAYERS II-103 Abbott Diabetes Care, Inc. (USA) II-103 Abiomed, Inc. (USA).............. II-103 Asahi Kasei Medical Co., Ltd. (Japan) II-103 Baxter International, Inc. (USA) II-104 F.Hoffmann-La Roche Ltd. (Switzerland) II-104 Fresenius Medical Care AG and Co. KGaA (Germany) II-105 HeartWare International, Inc. (USA) II-105 Jarvik Heart, Inc. (USA)..............II-105 Medtronic, Inc. (USA)..............II-106 Nikkiso Co., Ltd. (Japan)..............II-106 Nipro Corporation (Japan)..............II-106 SynCardia Systems, Inc. (USA)..............II-107 Terumo Heart, Inc. (USA)..............II-107 Thoratec Corp. (USA)..............II-107 Toray Medical Co., Ltd. (Japan)..............II-108 Vital Therapies, Inc. (USA)..............II-108 Xenios AG (Germany).............. II-108

14. GLOBAL MARKET PERSPECTIVE..............II-109 Table 37: World Recent Past, Current and Future Analysis for Artificial Organs by Geographic Region - US and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............II-109

Table 38: World Historic Review for Artificial Organs by Geographic Region - US and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) II-110

Table 39: World 14-Year Perspective for Artificial Organs by Geographic Region - Percentage Breakdown of Dollar Sales for US and Rest of World Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) II-111

Table 40: World Recent Past, Current and Future Analysis for Artificial Organs by Product Segment - Artificial Heart, Artificial Kidneys, Artificial Liver, Artificial Pancreas and Artificial Lungs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) II-112

Table 41: World Historic Review for Artificial Organs by Product Segment - Artificial Heart, Artificial Kidneys, Artificial Liver, Artificial Pancreas and Artificial Lungs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............II-113

Table 42: World 14-Year Perspective for Artificial Organs by Product Segment - Percentage Breakdown of Dollar Sales for Artificial Heart, Artificial Kidneys, Artificial Liver, Artificial Pancreas and Artificial Lungs Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) II-114

Table 43: World Recent Past, Current and Future Analysis for Artificial Kidneys/Dialyzers by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Africa, and Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) II-115

Table 44: World Historic Review for Artificial Kidneys/Dialyzers by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Africa, and Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) II-116

Table 45: World 14-Year Perspective for Artificial Kidneys/Dialyzers by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Africa, and Latin American Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).............. II-117

Table 46: World Recent Past, Current and Future Analysis for Insulin Pumps (External) by Geographic Region - US, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2015 through 2022 (includes corresponding Graph/Chart)..............II-118

Table 47: World Historic Review for Insulin Pumps (External) by Geographic Region - US, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2009 through 2014 (includes corresponding Graph/Chart).............. II-119

Table 48: World 14-Year Perspective for Insulin Pumps (External) by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for Years 2009, 2016 and 2022 (includes corresponding Graph/Chart) II-120

III. MARKET

1. THE UNITED STATES.............. III-1 A.Market Analysis.............. III-1 SynCardia's temporary Total Artificial Heart: The Only FDA Approved Artificial Heart..............III-1 Ageing Demographics: A Major Driving Factor for Artificial Organs Market.............. III-2 Table 49: North American Elderly Population by Age Group: 1975-2050 (includes corresponding Graph/Chart) III-2 Surging Diabetic Population Spurs Demand III-3 Table 50: Prevalence of Diabetes Mellitus in North America (2013 and 2035): Number of People with DM (in Thousands) in the 20-79 Age Group for the US, Canada and Mexico (includes corresponding Graph/Chart)..............III-3

Table 51: The US Diabetics Population (2010-2017): Percentage Population with Diagnosed and Undiagnosed Diabetes (includes corresponding Graph/Chart) III-4

Table 52: The US Diabetes Prevalence (in 000's) for 2010-2017P (includes corresponding Graph/Chart) III-5

Table 53: Diabetes Prevalence in the US by Type: 2013 (includes corresponding Graph/Chart) III-5

Table 54: Diabetes Prevalence by Ethnicity (includes corresponding Graph/Chart)..............III-6 Artificial Pancreas System (APS): The Future of Diabetes Management.............. III-6 Artificial Pancreas Status in the US III-8 Wearable Artificial Kidney Holds Promise to Transform Dialysis III-8 Product Introduction..............III-9 Strategic Corporate Developments III-9 Focus on Select Key Players..............III-11 B.Market Analytics..............III-16 Table 55: The US Recent Past, Current and Future Analysis for Artificial Organs Market Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-16

Table 56: The US Historic Review for Artificial Organs Market Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-17

2. REST OF WORLD.............. III-18 A.Market Analysis.............. III-18 Table 57: Dialysis Patient Population by Geographic Region/Country (2014-2018): Breakdown of Patient Population for Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World (includes corresponding Graph/Chart) III-19

Table 58: Prevalence of Diabetes Mellitus in Europe (2013 and 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 47 Countries in the Region III-20

Table 59: Prevalence of Diabetes Mellitus in South East Asia (2013 and 2035): Number of People with DM (in thousands) in the 20-79 Age Group for Bangladesh, Bhutan, India, Maldives, Mauritius, Nepal, and Sri Lanka III-21

Table 60: Prevalence of Diabetes Mellitus in Western Asia, Pacific Regions (2013 and 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 27 Countries in the Region.............. III-21

Table 61: Prevalence of Diabetes Mellitus in South and Central America (2013 and 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 20 Countries in the Region.............. III-22

Table 62: Prevalence of Diabetes Mellitus in Africa (2013 and 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 27 Countries in the Region III-23

Table 63: Prevalence of Diabetes Mellitus in Middle East and North Africa (2013 and 2035): Number of People with DM (in thousands) in the 20-79 Age Group for 19 Countries in the Region.............. III-24 New Artificial Pancreas System to Improve Diabetes Management III-24 EU-Supported Artificial Pancreas Project to Provide Competitive Edge to Europe..............III-25 Product Introduction..............III-26 Strategic Corporate Developments III-26 Focus on Select Players..............III-27 B.Market Analytics..............III-30 Table 64: Rest of World Recent Past, Current and Future Analysis for Artificial Organs Market Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-30

Table 65: Rest of World Historic Review for Artificial Organs Market Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-31

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 48 (including Divisions/Subsidiaries - 56)

The United States (25) Japan (10) Europe (15) - France (3) - Germany (5) - The United Kingdom (2) - Rest of Europe (5) Asia-Pacific (Excluding Japan) (4) Middle East (2)

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Transplant Diagnostics: Technologies and Global Markets

Transplant Diagnostics: Technologies and Global Markets

  • $ 6650
  • Industry report
  • October 2016
  • by BCC Research

Use this report to: - Identify key market segments - Gain insight into the trends, gaps, and opportunities in each of the micro markets. - Learn about the key market dynamics and the factors impacting ...

Implantable Medical Devices Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Implantable Medical Devices Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • August 2016
  • by Transparency Market Research

This report on implantable medical devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture ...

Urology Surgical Instruments Market by Product, Application - Global Forecast to 2021

Urology Surgical Instruments Market by Product, Application - Global Forecast to 2021

  • $ 5650
  • Industry report
  • September 2016
  • by MarketsandMarkets

The global urology surgical instruments market is expected to reach USD 11.48 billion by 2021 from USD 7.74 billion in 2016, growing at a CAGR of 8.2% from 2016 to 2021. The consumables and accessories ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.